Reported results
- Net loss was $29.0 million for the three months ended September 30, 2026, compared to $21.0 million for the three months ended September 30, 2025.
- Research & Development expenses were $23.5 million for the three months ended September 30, 2026, compared to $17.2 million for the three months ended September 30, 2025.
- General & Administrative expenses were $8.9 million for the three months ended September 30, 2026, compared to $6.6 million for the three months ended September 30, 2025.
- Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026.
Guidance
- Cash, cash equivalents and short-term investments are expected to fund planned operations into the first quarter of 2029.
- Topline data from the Embolden registrational trial is anticipated in the second half of 2027.
- Process Performance Qualification (PPQ) runs are on track to be completed by year-end 2026.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.
